5:59 PM
Oct 25, 2012
 |  BC Extra  |  Company News

NICE reverses prior decision, backs Bronchitol for CF subgroup

The U.K.'s NICE issued new draft guidance recommending Bronchitol mannitol from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) as an add-on therapy to best standard of care in cystic fibrosis patients, but in a narrower CF population than the one the committee rebuffed earlier this year. The committee...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >